Finland
Linio Biotech, founded in 2017, is spearheading innovation in the Biotechnology and Life Sciences industries with its proprietary Tience® technology. This Finland-based company aims to redefine aesthetic medicine through the development of groundbreaking regenerative injectables, promising a shift away from temporary fillers and invasive procedures.
Dedicated to natural tissue augmentation, Linio Biotech delivers a product that is both safe and biologically active, fostering sustainable and natural tissue regeneration. The company's flagship technology is already commercialized in the Nordics, backed by clinical research and substantial real-world data. With a recent early-stage investment of €4.20M, Linio Biotech is poised to extend its innovative solutions globally, presenting a compelling opportunity for investors looking at next-gen solutions in aesthetic healthcare.
